Hemogenyx Pharmaceuticals (LON:HEMO) Trading 2.4% Higher – Here’s Why

Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO) shot up 2.4% during trading on Friday . The company traded as high as GBX 642 and last traded at GBX 642. 8,467 shares were traded during trading, a decline of 61% from the average session volume of 21,607 shares. The stock had previously closed at GBX 627.

Hemogenyx Pharmaceuticals Stock Up 2.4%

The firm has a market cap of £38.78 million, a P/E ratio of -2.78 and a beta of 3.14. The firm’s fifty day moving average is GBX 652.50 and its 200 day moving average is GBX 644.83. The company has a debt-to-equity ratio of 90.87, a quick ratio of 6.72 and a current ratio of 4.38.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.